Magazine
Sign up for your free subscription and keep up-to-date.
Upcoming Events
Newsletters
Stay updated on the latest news and technologies with Bioscienceworld's newsletters.
Five to choose from.
November 2009
Volume 12, Issue 11
|
A molecular switch between scarring and central nervous system regeneration
By Sandy Vascotto and Arthur Brown
Salamanders and other evolutionarily primitive animals are capable of regenerating complex structures that serve as inspiration to modern medicine. Even such sensititve systems as severed spinal cords are regrown to full functionality in short order. Humans are not nearly so adept at regeneration. A simple event like an uninformed dive into a swimming pool, automobile accident, slip on a set of stairs, or mere progression of the normal process of aging can have a profound impact upon an individual’s capacity to maintain an independent existence. |
|
Canadian biotech companies get set to learn a new language of financial reporting
Compiled by Shawn Lawrence
By Jan. 1, 2011, small and medium Canadian biotechnology private companies will need to decide what standard to use in reporting their financial statements, choosing whether to adopt Canadian Generally Accepted Accounting Principles (GAAP) for Private Enterprises or adopt International Financial Reporting Standard (IFRS). While private companies will have a choice, publicly traded companies will not have this option, they must use IFRS. |
|
Building a cancer treatment from a virus: Matt Coffey Chief Operating Officer Oncolytics Biotech Inc.
Compiled by Shawn Lawrence
Chemotherapy as any cancer patient will tell you isn’t for the faint of heart but it can kill many forms of cancer. Some forms of chemotherapy, originally discovered as a cancer treatment almost 70 years ago, are still routinely prescribed for most types of the disease. |
|
Biotech professionals making a difference
By Christine Beyaert
Access to talent continues to be a prominent issue in the life sciences industry. Better talent can be developed through mentoring and experienced professionals can be accessed through a stronger network within the life sciences industry. |
|
Mergers and acquisitions activity in Canada: Is it a solution to the funding crisis?
By Michael Herman
At the recent BioContact Symposium in Québec City, I overheard a conversation between the CEOs of two Canadian biotechnology companies. The CEOs had just attended a seminar on innovative funding strategies in the new economy. One of the CEOs said to the other that while the seminar was interesting, he did not hear the speakers say anything that was going to help him solve his company’s acute immediate funding crisis. I was struck by the frustration and resignation in this CEO’s voice. I do not think he was criticizing the speakers. Rather, he was acknowledging an unfortunate reality in today’s environment that no one seems to have any good answers to the question of where he can find funding to keep his company alive. |
|
Looking back at the decade that was for Biotech
By Robert Foldes
I am privileged to be able to communicate my thoughts on the state of the biotechnology sector as we close out the decade. I decided to focus my comments on the area I know best - the human health segment of this sector in Ontario. |
